Malapuram Vasudha Reddy, MD
Endocrinology, Diabetes & Metabolism · Huntsville, ALNPI 1043634991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 376 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 376 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Dexcom, Inc.$707
- Sanofi-aventis U.S. LLC$475
- Medtronic$474
- Insulet Corporation$413
- Abbott$344
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$872%
- Food & beverage$5,35297%
- Education$130%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 113 | $1,226 |
| Dexcom, Inc. | 48 | $707 |
| Sanofi-aventis U.S. LLC | 28 | $475 |
| Medtronic(2 entities) | 35 | $474 |
| Insulet Corporation | 23 | $413 |
| Abbott | 22 | $344 |
| Xeris Pharmaceuticals, Inc. | 16 | $307 |
| AstraZeneca | 11 | $193 |
| Amgen(2 entities) | 9 | $136 |
| Tandem Diabetes Care, Inc. | 7 | $123 |
| AbbVie | 7 | $123 |
| Mannkind Corporation | 5 | $122 |
| Bayer | 5 | $109 |
| Boehringer Ingelheim | 5 | $84 |
| Corcept Therapeutics | 5 | $82 |
| Lilly USA, LLC | 5 | $79 |
| Johnson & Johnson | 5 | $71 |
| Pfizer | 4 | $65 |
| Zealand Pharma US, Inc. | 4 | $62 |
| IBSA Pharma Inc. | 4 | $57 |
| Radius Health, Inc. | 2 | $35 |
| Recordati_rare_diseases_inc. | 1 | $32 |
| GRT US Holding, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $26 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Novartis | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Abiomed | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$125
How this compares
$5,511 in reported general payments places this provider in the 40th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 565 | $865,934 |
| MounjaroTirzepatide | 574 | $849,283 |
| JardianceEmpagliflozin | 499 | $618,838 |
| Tresiba Flextouch U-100Insulin Degludec | 287 | $361,377 |
| TrulicityDulaglutide | 210 | $292,366 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 135 | $212,618 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 400 | $82,208 |
| FarxigaDapagliflozin Propanediol | 65 | $67,734 |
| SynjardyEmpagliflozin/Metformin Hcl | 32 | $46,149 |
| HumalogInsulin Lispro | 94 | $37,569 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $31,218 |
| FiaspInsulin Aspart (Niacinamide) | 12 | $29,295 |
| Humalog Kwikpen U-100Insulin Lispro | 61 | $26,776 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $25,917 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $24,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Humulin 70-30 | $79 | $1,196,886941 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $1,226 | $925,567610 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Glyxambi | $84 | $700,106565 claims |
| AstraZenecaFarxiga | $193 | $67,73465 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $475 | $22,25937 claims |
| AmgenProlia | $136 | $20,51912 claims |
| AbbVieSynthroid | $123 | $4,58549 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Huntsville
- Dwain WoodeHuntsville$78K
- Ankur JindalHuntsville$6K
- Joshua TateHuntsville$5K
- Bobby JohnsonHuntsville$4K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.